MPLT at a glance
MapLight Therapeutics, Inc. (MPLT, SEC CIK 1770069) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 19 institutional investment managers tracked by SignalX reported holding MapLight Therapeutics, Inc. (MPLT) shares worth $88.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kreitzer Anatol on October 15, 2026 of 12,248 shares at $7.84 per share.
- In the last 90 days, MPLT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$1.3M
- 13F holders
- 19 funds
- $88.1M · −2 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 may affect a CDMO and restrict certain Chinese biotechnology suppliers
- Most materially updated regulatory risk: OBBBA signed July 4, 2025 may reduce ACA coverage and Medicaid enrollment
- Clinical risk: IRIS Phase 2 failed its primary endpoint in June 2026
- Operational risk: ML-007C-MA relies on limited single-source manufacturing suppliers
- Financial risk: $463.4 million cash, equivalents and investments expected to fund operations through 2028
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- Operating margin not applicable, operating loss $55.3M vs $31.5M YoY
- R&D expenses $44.2M vs $27.1M, driven by clinical trials and employee costs
- Cash, equivalents and investments $463.4M; operating cash used $131.7M
- Outlook: cash expected to fund operations through 2028, further funding required thereafter
AI summary of the MPLT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation signals refreshed investor messaging as of November 16, 2026
- Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.2
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Investor-relevant figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 net loss $51.6M, versus $29.4M, reflecting sharply higher clinical development spending
- Cash, equivalents and investments $463.4M, expected to fund operations through 2028 and key clinical readouts
Item EX-99.2: Item EX-99.2
- Corporate presentation dated November 16, 2026 highlights ML-007C-MA as the lead schizophrenia and Alzheimer’s disease psychosis asset
- ZEPHYR-1 met its primary endpoint, with PANSS effect size 0.37 and cognitive composite effect size 0.51
Item 1.01: Entry into a Material Definitive Agreement
- ATM facility authorizes up to $100 million in common-stock sales, providing MapLight flexible funding access
- Potential equity issuance creates shareholder dilution risk, depending on shares sold
Item 1.01: Entry into a Material Definitive Agreement
- $150.0 million gross private placement, strengthening funding for MapLight’s operations and development programs
- 9,197,887 common shares plus pre-funded warrants for 3,983,168 shares at $11.38 per share, creating substantial dilution
Item 3.02: Unregistered Sales of Equity Securities
- Unregistered securities issued in a private placement under Securities Act Section 4(a)(2)
- Securities subject to resale restrictions absent registration or another exemption
Item EX-99.3: Item EX-99.3
- August 13 presentation highlights ML-007C-MA as MapLight’s lead asset, with schizophrenia Phase 3 planning and Alzheimer’s disease psychosis results expected in 2H 2027
- ZEPHYR Phase 2 met its primary endpoint, PANSS effect size 0.37 mITT and 0.50 among completers, supporting planned registrational development
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation signals refreshed investor messaging and potentially new clinical, pipeline, or corporate milestones
- Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.3
Item EX-99.2: Item EX-99.2
- $150M PIPE financing, strengthening liquidity for late-stage clinical development
- 9,197,887 shares sold at $11.38, plus pre-funded warrants for 3,983,168 shares
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026, with full results in Exhibit 99.1
- Cash, cash equivalents and investments totaled $351.3 million at June 30, 2026
Item EX-99.1: Item EX-99.1
- Positive Phase 2 ZEPHYR results support planned registrational Phase 3 ZEPHYR-2 in schizophrenia, with topline results expected in 2028
- ML-007C-MA advanced as the lead asset across schizophrenia and ADP; VISTA enrollment ongoing with results expected in the second half of 2027
AI summaries of MPLT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MPLT
Don't miss the next MPLT filing
- Alerts as it files. A push when MPLT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MPLT, by share count.
- Ask anything. An AI agent that reads every MPLT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kreitzer Anatol | Sell | Oct 15, 2026 | 12,248 | $7.84 |
| Kroeger Christopher A. | Sell | Oct 15, 2026 | 73,691 | $8.08 |
| GILLIS JONATHAN | Sell | Oct 15, 2026 | 10,167 | $8.08 |
| Lillie James Woodruff | Sell | Oct 15, 2026 | 11,513 | $8.08 |
| Hanson Kristopher | Sell | Oct 15, 2026 | 9,020 | $8.08 |
| Foff Erin Pennock | Sell | Oct 15, 2026 | 15,355 | $8.08 |
| Hanson Kristopher | Sell | Sep 16, 2026 | 16,509 | $11.67 |
| GILLIS JONATHAN | A | Aug 17, 2026 | 6,020 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | - | -$82.9M | -$169.1M |
| Net Income | - | -$77.6M | -$161.2M |
| Balance Sheet | |||
| Total Assets | - | $136.9M | $479.5M |
| Equity | -$117.6M | -$193.6M | $458.4M |
| ROE | - | 40.1% | -35.2% |
| Per Share | |||
| EPS | - | $-105.38 | $-18.56 |
| Cash Flow | |||
| Operating CF | - | -$78.8M | -$138.1M |
| CapEx | - | $770K | $473K |
Source: XBRL data in MapLight Therapeutics, Inc. (MPLT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MPLT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 19 | $88.1M |
| Q2 2026 | 21 | $265.4M |
| Q1 2026 | 16 | $103.7M |
| Q4 2025 | 16 | $81.8M |
- Goldman Sachs Group+1.65M (+85%)
- BlackRock+687.6K (+67%)
- Two Sigma Investments+507.0K (+5635%)
- Millennium Management+294.8K (+229%)
- Citadel Advisors LLC+59.7K (+232%)
- State Street Corp−538.6K (-63%)
- Vanguard Capital Management LLC−388.1K (-49%)
- T. Rowe Price Group−290.6K (-20%)
- Bank of America Corp−38.4K (-70%)
- Wells Fargo & Co−5.7K (-60%)
- D.E. Shaw & Co+29.4K
- Fifth Third Bancorp+574
- FMR LLC (Fidelity)−823.6K
- Renaissance Technologies LLC−6.9K
- Raymond James Financial−6.5K
- Invesco Ltd−5.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 72 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MPLT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| SC 13G | Aug 20, 2026 | - | - | |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 4 | Jul 20, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MPLT SEC filings: frequently asked questions
Are MPLT insiders buying or selling?
In the last 90 days, MapLight Therapeutics, Inc. (MPLT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $1.3 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MPLT stock?
As of September 30, 2026, the largest MapLight Therapeutics, Inc. (MPLT) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($36.7 million), BlackRock ($17.5 million), T. Rowe Price Group ($11.5 million), Two Sigma Investments ($5.3 million), Millennium Management ($4.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did MPLT report in its latest 8-K?
MapLight Therapeutics, Inc. (MPLT) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Updated corporate presentation signals refreshed investor messaging as of November 16, 2026.
What are the latest MPLT SEC filings?
MapLight Therapeutics, Inc. (MPLT) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 16, 2026.
What is MPLT's SEC CIK number?
MapLight Therapeutics, Inc. (MPLT)'s SEC Central Index Key (CIK) is 1770069. EDGAR lists every MPLT filing under that number.
Ask anything about MPLT
The research agent reads MPLT's filings, financials, insider trades and 13F holders, then answers with sources.